Suboxone Lawsuit Timeline: From FDA’s Dental Warning to Bellwether Records

January 2022: FDA identifies a dental safety problem

On January 12, 2022, FDA issued a Drug Safety Communication about dental problems reported with buprenorphine medicines dissolved in the mouth. The agency described cavities, oral infections, tooth decay, erosion, abscesses, fractures, and tooth loss, including reports in people without a prior dental history. It required a new warning and patient-medication-guide information for transmucosal products. The communication covered a route of administration, not only brand-name Suboxone film.

FDA also stressed that buprenorphine’s benefits for opioid use disorder outweigh these risks and warned patients not to stop treatment suddenly. It recommended a baseline dental examination, regular dental follow-up, and rinsing the teeth and gums with water after the medicine dissolves, followed by waiting at least one hour before brushing. A safety warning supports clinical vigilance; it is not an adjudication of legal causation or damages.

February through June 2024: a federal MDL takes shape

On February 2, 2024, the JPML centralized 15 actions in the Northern District of Ohio before Judge J. Philip Calabrese. The panel identified shared allegations that Suboxone film’s acidity and prolonged contact with teeth caused erosion and decay and that warnings were inadequate. The transfer order coordinated recurring factual questions; it did not decide that the film caused any plaintiff’s condition or that a defendant was liable.

The court held an initial conference, appointed leadership, authorized direct filing, and adopted a “Schedule A” complaint process. On June 24, 2024, it denied a defense request to phase discovery around general causation first. The ruling left open how later Rule 702 expert challenges might be grouped. Denial of phased discovery was a scheduling and management decision, not a finding that plaintiffs had proved general causation.

Late 2024: pleadings survive in part and the census begins

A September 10, 2024 opinion dismissed certain corporate defendants without prejudice. On November 4, Case Management Order 12 established a census protocol for plaintiffs with cases filed on or before October 7, requiring information and initial proof related to product use and dental injury. The census was designed to identify and organize filed claims; completing it was not a merits win or settlement qualification.

On December 31, the court granted in part and denied in part a motion to dismiss. That familiar mixed result allowed portions of the coordinated litigation to continue while narrowing others. It did not create a class, set damages, or resolve fact-specific questions. Readers should distinguish a pleading ruling—whether allegations may proceed at that stage—from proof after discovery and admissible expert evidence.

2025: the court selects records for bellwether development

On March 14, 2025, Case Management Order 15 established a bellwether protocol and Record Collection Pool. Later orders identified randomly selected plaintiffs, amended the pool, and required medical, pharmacy, and dental records. Bellwether development is a sampling and case-preparation tool. A place in the pool is not a prediction that the case will be tried, win, or receive a particular value.

In September 2025, the court issued show-cause orders to plaintiffs who had not submitted required census material. An October 9 opinion dismissed some claims with or without prejudice and allowed others to continue based on good cause, while directing an updated pool list. Those case-management consequences help explain why historical and pending JPML totals differ. They are not a settlement event and should not be described as one.

2026: records work continues under an amended protocol

On March 27, 2026, the court issued a second amended bellwether protocol. A March 31 records order explained that timely production was necessary to obtain proof of Suboxone film use, dental records, and other materials. On June 5, it amended the common-benefit order, and on July 2 it reappointed plaintiffs’ leadership. These are signs of active coordinated litigation, not a final resolution.

JPML reported 1,832 actions pending and 1,908 historical on July 1, 2026. The official court page reviewed through July 11 did not announce a universal settlement or public award schedule. The next meaningful developments will come from court orders addressing selected cases, experts, discovery, or trial planning. Patients should continue treatment decisions with clinicians; legal marketing should not turn an active MDL into medical advice or a promised recovery.

Reader questions

Frequently asked questions